Halozyme (NASDAQ: HALO) CFO awarded new performance stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Halozyme Therapeutics executive Nicole LaBrosse, SVP and Chief Financial Officer, reported new equity awards tied to prior performance-based grants. On February 9, 2026, she acquired 5,167, 7,448, and 29,502 performance stock units at $0 per unit, each representing a contingent right to one share of common stock.

The units reflect the company’s determination of how many stock units became eligible to vest based on performance periods ending December 31, 2025 for PSU awards originally granted in 2023, 2024, and 2025. These awards remain subject to continued service through the third anniversary of each original grant date.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider LaBrosse Nicole

Role SVP, CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Performance Stock Units	5,167	$0.00	--
Grant/Award	Performance Stock Units	7,448	$0.00	--
Grant/Award	Performance Stock Units	29,502	$0.00	--

Holdings After Transaction: Performance Stock Units — 13,351 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Form 4 Insider Transactions: What Each Field Means →

02/11/2026 - 09:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaBrosse Nicole

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Units	$0	02/09/2026		A		5,167		⁽¹⁾	⁽¹⁾	Common Stock	5,167	$0	13,351	D
Performance Stock Units	$0	02/09/2026		A		7,448		⁽²⁾	⁽²⁾	Common Stock	7,448	$0	43,045	D
Performance Stock Units	$0	02/09/2026		A		29,502		⁽³⁾	⁽³⁾	Common Stock	29,502	$0	29,502	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Halozyme (HALO) report for Nicole LaBrosse?

Halozyme reported that CFO Nicole LaBrosse acquired performance stock units on February 9, 2026. The awards are equity compensation, not open-market purchases, and reflect shares that became eligible to vest based on performance through December 31, 2025, subject to continued service.

How many performance stock units did the Halozyme CFO receive in this Form 4?

The CFO received three blocks of performance stock units: 5,167, 7,448, and 29,502 units. Each unit represents a contingent right to one share of Halozyme common stock, with actual vesting dependent on satisfying ongoing service-based requirements after the performance period.

What is the transaction code used in Halozyme CFO Nicole LaBrosse’s Form 4?

The Form 4 uses transaction code “A”, indicating a grant, award, or other acquisition of derivative securities. These performance stock units are part of the company’s equity compensation program rather than market trades, and were awarded at a stated price of $0 per unit.

Are the performance stock units for Halozyme (HALO) CFO fully vested now?

No, the units are not fully vested. The company determined how many units became eligible based on performance through December 31, 2025, but they remain subject to a service-based requirement through the third anniversary of each original performance stock unit grant date.

What performance periods apply to the Halozyme CFO’s reported performance stock units?

The footnotes state that the units relate to PSU awards originally granted on February 16, 2023, February 23, 2024, and February 20, 2025. Each award used a performance measurement period ending December 31, 2025 to determine how many stock units became eligible to vest.

Does the Halozyme CFO’s Form 4 indicate direct or indirect ownership of these units?

The filing shows the performance stock units as directly owned. The ownership code is listed as “D” for direct, and there is no separate entity or indirect nature-of-ownership disclosure associated with these particular derivative securities in the provided data.